Bone mineral density in sclerosteosis; affected individuals and gene carriers - sprookjes - yvandenbroek - TriplyDB

Bone mineral density in sclerosteosis; affected individuals and gene carriers

Bone mineral density in sclerosteosis; affected individuals and gene carriers

http://www.wikidata.org/entity/Q28274370

about

Control of the SOST bone enhancer by PTH using MEF2 transcription factors Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Sclerostin Inhibition in the Management of Osteoporosis From disease to treatment: from rare skeletal disorders to treatments for osteoporosis Emerging Therapies for Osteoporosis Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.Profile of romosozumab and its potential in the management of osteoporosis.Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis.Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts Sclerostin: current knowledge and future perspectives.Emerging therapies in metastatic bone pain.A roadmap to the brittle bones of cystic fibrosis.Romosozumab for the treatment of osteoporosis.Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis 'Sink or swim': an evaluation of the clinical characteristics of individuals with high bone mass Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives Mechanical load increases in bone formation via a sclerostin-independent pathway.Targeted deletion of Sost distal enhancer increases bone formation and bone mass Wnt signaling in bone development and disease: making stronger bone with Wnts The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6 The osteoporosis revolution marches on.Dental and periodontal phenotype in sclerostin knockout mice.Targeting subchondral bone for treating osteoarthritis: what is the evidence?Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases.Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis.Sclerostin: therapeutic horizons based upon its actions.Status of drug development for the prevention and treatment of osteoporosis.Osteoporosis therapy: a novel insight from natural homeostatic system in the skeleton.Perspectives on osteoporosis therapies.Sclerostin and skeletal health.TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.Sclerosteosis caused by a novel nonsense mutation of SOST in a consanguineous family.High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.APC mutations are associated with increased bone mineral density in patients with familial adenomatous polyposis.Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.WNT-mediated Modulation of Bone Metabolism: Implications for WNT Targeting to Treat Extraskeletal Disorders.Monoclonal antibodies for treating osteoporosis.

P2860

Q24337339-05DC523D-5488-46A4-B243-247BE2E96A95 Q26744599-B811C970-7B48-4A80-8DE7-D5E499F52DD5 Q26750713-5E80FE78-1B73-4A33-9F6B-B7460499C1E0 Q26764854-248D8BAC-8E16-4A68-B9F6-E0508EFDBA79 Q26782109-A725865B-761E-45E5-859B-5E36A132A979 Q27022580-DCD96625-C1F6-422C-B4CB-4D37F14EEFB0 Q33564617-BEA3DB8C-D570-4AFF-85D5-81E89D2335AA Q33596475-B0B5ABC8-FEA2-4218-96A3-8F2A012E9BC8 Q33712272-C6DB1424-7EBD-4A34-95BF-C0614CA43738 Q33895465-DB00C08A-9357-466F-9F49-5E2DA28F57B4 Q33992612-B1B9029A-9195-45B4-90F5-27E47EBF870F Q34182919-0EC558AF-2A5E-4BD4-A1B1-79E1F1EF0051 Q34442832-15F84FAA-029B-45E7-8665-8188AA1D889C Q34680463-CCC212BF-770E-4A08-924F-AAF27BD3EB80 Q35507830-A7EF7891-430D-48BB-80B2-59B587194C6D Q35681137-2A979B46-A504-4498-AD5F-4C2634DE92B0 Q35694436-D9168AD2-A5C8-4D1E-B5E9-C782BE170ED3 Q35744492-E008B7BA-4AA2-4EA8-B8C8-5E033BB40666 Q35850660-6E903A95-2C5A-4E21-91A4-9454AF993E5A Q36212807-6BE64005-A104-421A-B359-7D671E8110DD Q36418026-EE91729D-F70A-4113-A4FC-44A7CF0CA8B8 Q37224687-DBFEE3EA-BD36-42F3-89CB-011865D9B1DE Q37426033-0BC09EE4-68EC-4DD3-ABC3-C526693F6DD2 Q37458063-2C52C6DF-5C1E-45BB-BE1D-A5A9E7B50F79 Q37596611-39336F4E-2D35-4FCA-AE47-56EA7B88857D Q37640833-D827BFD2-EBEB-411B-A602-7C3A9353B619 Q37813135-73E8189D-6DC7-47DB-B0C5-A97E5D8B334F Q37974871-B41EC829-0D97-463C-8F5F-407D422EF078 Q38184588-AD4941C3-4608-4F49-B548-3CB7D2BD2F5A Q38257484-B82878A9-984F-44C7-90B9-04EDCA2FDB83 Q38313739-F4AB4706-410B-43B7-9442-5A6DEA6CB6CB Q38351116-F410B08D-6F44-4B6E-A3BF-C57E8CE4E76F Q39155183-DBD7DCED-BDEF-45A7-81B5-DE8A598D6AE9 Q40217824-B3CBD2CD-A5F1-4963-9C01-868FB6D9B028 Q40631856-8CEF6CFA-4375-44F6-9156-4ABCCC7C3D99 Q42262347-8896EB78-27EA-48C9-8071-421D32BEAA3B Q43011731-E34FE885-1301-4E1E-A4C4-3C4957963878 Q43879015-0CC572A2-1591-46BC-902C-A5C1C52B6F12 Q47378873-409CE6B2-EEC4-484A-A241-3440FBA4AEEC Q47638169-0417A5BF-0B4E-4C31-9C45-19665F32C1CA

P2860

Bone mineral density in sclerosteosis; affected individuals and gene carriers

http://www.wikidata.org/entity/Q28274370

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@ast

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@en

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@nl

type

label

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@ast

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@en

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@nl

prefLabel

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@ast

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@en

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@nl

P1433

Q28274370-00190039-D9D0-4CC3-8AC9-A33C2F5C41C1

P1476

Q28274370-BB3FDA46-0ACC-40E0-B7FC-1C7718D86A43

P2093

Q28274370-1D2C143C-B5CD-45AD-81F5-BF664DE8E85F

Q28274370-2E221399-47A1-4A38-A333-B3F8ED090A44

Q28274370-848138EC-710C-42DE-A81B-E59B66F328D2

Q28274370-C179B912-4219-46B5-9F8E-985416173FDD

Q28274370-C54A005D-1F2C-40DB-8090-BFC11DE347D3

Q28274370-E4AE4588-C911-424F-9D1A-7FD79EBAB1B3

Q28274370-E596B3E8-A245-4BD8-AFB4-D5E9A7701BEE

Q28274370-FC30237D-EA65-445D-86CE-EB5B1D6C0F32

P304

Q28274370-8F264E43-3E02-4B44-985A-B9B662DE5E28

P31

Q28274370-452D6B2D-7FCA-4B3B-81DE-75B84D56480D

P3181

Q28274370-C04E9801-D2FE-4B04-A480-91495F01107A

P356

Q28274370-258831AA-778B-4068-A18E-43DD277D55C4

P407

Q28274370-91097798-C8D9-48B2-AA76-EF946D12943C

P433

Q28274370-C864A317-A8F0-4DA4-9F21-BB38C9DE969B

P478

Q28274370-94D0CBC2-07EB-4DE3-A96E-8E9750B6A8D6

P577

Q28274370-5122707D-F8FA-4918-9E22-32CE3E770C6D

P5875

Q28274370-951E7756-12F8-40BB-B05A-DBB411A79DDA

P698

Q28274370-6A2D7B34-6509-4F52-B235-F8C091CD8500

P3181

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Bone mineral density in sclerosteosis; affected individuals and gene carriers

@en

P2093

Benjamin Mervis

http://www.w3.org/2001/XMLSchema#string

Clemens W G M Löwik

http://www.w3.org/2001/XMLSchema#string

Herman Hamersma

http://www.w3.org/2001/XMLSchema#string

Jessica C Gardner

http://www.w3.org/2001/XMLSchema#string

Neveen A T Hamdy

http://www.w3.org/2001/XMLSchema#string

Peter Beighton

http://www.w3.org/2001/XMLSchema#string

Rutger L van Bezooijen

http://www.w3.org/2001/XMLSchema#string

Socrates E Papapoulos

http://www.w3.org/2001/XMLSchema#string

P304

6392-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1271082

http://www.w3.org/2001/XMLSchema#string

P356

10.1210/JC.2005-1235

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7575741

http://www.w3.org/2001/XMLSchema#string

P698

16189254

http://www.w3.org/2001/XMLSchema#string